Systematic Review of Recommendations on the Use of Disease‐Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Cancer
- 1 March 2019
- journal article
- review article
- Published by Wiley in Arthritis Care & Research
- Vol. 72 (3) , 309-318
Abstract
Objective: To evaluate consensus recommendations regarding management of rheumatoid arthritis (RA) in patients with cancer.Methods: We searched electronic databases, guideline registries, and relevant web sites for cancer‐specific recommendations on RA management. Reviewers independently selected and appraised the recommendations according to the Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument. We identified similarities and discrepancies among recommendations.Results: Of 4,077 unique citations, 39 recommendations were identified, of which half described their consensus process. Average scores for the AGREE II domains ranged from 33% to 87%. Cancer risk in RA was addressed in 79% of recommendations, with acknowledgement of increased overall cancer risk. Recommendations did not agree on the safety of using disease‐modifying antirheumatic drugs (DMARDs) in RA patients with cancer, except for the contraindication of tumor necrosis factor inhibitors in patients at risk for lymphoma. Most recommendations agreed that RA treatment should be stopped and re‐evaluated with a new diagnosis of cancer. Recommendations for patients with a history of cancer differed depending on the drug, cancer type, and time since cancer diagnosis. Few recommendations addressed all issues.Conclusion: Recommendations for the treatment of RA in patients with cancer often fail to meet expected methodologic criteria. There was agreement on the need for caution when prescribing DMARDs to these patients. However, several areas continue to lack consensus, and given the paucity of evidence, there is an urgent need for research and expert opinion to guide and standardize the management of RA in patients with cancer.Keywords
This publication has 37 references indexed in Scilit:
- Abatacept therapy and safety managementJoint Bone Spine, 2012
- Canadian guidelines for clinical practice: an analysis of their quality and relevance to the care of adults with comorbidityBMC Family Practice, 2011
- Quality appraisal of clinical practice guidelines on the use of physiotherapy in rheumatoid arthritis: a systematic reviewRheumatology, 2011
- Updated consensus statement on the use of rituximab in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2011
- Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of RheumatologyClinical Rheumatology, 2010
- BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapiesRheumatology, 2010
- Österreichische Empfehlungen zum Gebrauch von Methotrexat in der Rheumatologie – Expertenkonsensus basierend auf einer systematischen LiteratursucheAktuelle Rheumatologie, 2010
- A practical guide for the use of biologic agents in the treatment of rheumatoid arthritis*International Journal of Rheumatic Diseases, 2006
- Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE projectQuality and Safety in Health Care, 2003
- Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2000